Evolocumab

230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more

Peter Attia MD

A PCSK9 inhibitor (monoclonal antibody) that lowers LDL by 50-60% and Lp(a) by 25%, with positive cardiovascular outcome data from the FOURIER trial.